-
Mashup Score: 0Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 3 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 3 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @DanaFarber highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7sEOm https://t.co/I2AnSt68GO
-
-
Mashup Score: 0Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 3 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @NUFeinbergMed highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7sEOm https://t.co/RiGRVNypBV
-
-
Mashup Score: 1Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 3 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @NUFeinbergMed highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7sEOm https://t.co/F9rJidTBnC
-
-
Mashup Score: 1Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 3 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @NUFeinbergMed highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7sEOm https://t.co/dmWocotEbT
-
-
Mashup Score: 0Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 3 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @NUFeinbergMed highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7sEOm https://t.co/9fFNGZeUF2
-
-
Mashup Score: 14ANZUP Reports A New Class of Effective Therapy for Men with Metastatic Castration-Resistant Prostate Cancer - 3 year(s) ago
TheraP ANZUP 1603 clinical trial, 177Lu-PSMA-617 (Lu-PSMA), 177Lu-PSMA-617 (Lu-PSMA) compared to cabazitaxel for men with metastatic castration-resistant prostate cancer, updated study results from the TheraP study.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#TheraP: 177Lu-PSMA617 trial published in @TheLancet. #Cabazitaxel in patients with #mCRPC. #Congratulations on #GU21 data and simultaneous publication! Details on UroToday > https://t.co/0gu5bojPwe @DrMHofman @Prof_IanD @ANZUPtrials @zklaassen_md @WallisCJD @ASCO #ASCOGU #GU21 https://t.co/EQCYtqka2T
-
-
Mashup Score: 0
[¹⁷⁷Lu]Lu-PSMA-617 compared with cabazitaxel in men with mCRPC led to a higher PSA response, [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel, [¹⁷⁷Lu]Lu-PSMA-617 is a new effective class of therapy and a potential alternative to cabazitaxel.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
[¹⁷⁷Lu]Lu-PSMA-617 vs #Cabazitaxel in patients with metastatic castration-resistant #ProstateCancer #TheraP: a randomised, open-label, phase 2 trial. #Congratulations on the @TheLancet publication! #ReadNow > https://t.co/xt3ApLhIY1 @DrMHofman @drlouiseemmett @Prof_IanD https://t.co/cabSsTs607
-
-
Mashup Score: 4
[177Lu]Lu-PSMA-617 compared with cabazitaxel in men with metastatic castration-resistant prostate cancer led to a higher PSA response and fewer grade 3 or 4 adverse events. [177Lu]Lu-PSMA-617 is a new effective class of therapy and a potential alternative to cabazitaxel.
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet-
👏👏@DrMHofman @Prof_IanD @ANZUPtrials @ASCO #GU21 & simultaneous pub @TheLancet #LuPSMA vs #cabazitaxel #mCRPC s/p docetaxel n=200 pts w/ high PSMA-expression LuPSMA: ⬆️PFS @ 1y 19% vs 3%, HR 0.63 ⬆️ORR 49% vs 24% ⬇️Gr 3-4 AEs, Fatigue ⬆️Functioning https://t.co/qFJ9wPxH7r https://t.co/tKC4SRQbHP
-
-
Mashup Score: 0
Since cabazitaxel improved pain response, time to pain progression, time to symptomatic skeletal events, and EQ-5D-5L utility index, clinicians and patients with metastatic castration-resistant prostate cancer can be reassured that cabazitaxel will not reduce quality of life when compared with treatment with a second androgen signalling-targeted inhibitor.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in our Nov issue: #Qualityoflife in patients with metastatic #prostatecancer following treatment with #cabazitaxel versus #abiraterone or #enzalutamide—results from the CARD study #pcsm https://t.co/s2eZHTWy3i
-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @DanaFarber highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7b3pM https://t.co/d3VCAArOoh